Hims & Hers Health (NYSE:HIMS) Price Target Increased to $23.00 by Analysts at Bank of America

Hims & Hers Health (NYSE:HIMS) had its price objective hoisted by Bank of America from $20.00 to $23.00 in a research report released on Monday morning, Benzinga reports. Bank of America currently has a buy rating on the stock.

A number of other analysts also recently commented on the company. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a buy rating and a $24.00 price objective for the company. Imperial Capital downgraded Hims & Hers Health from an outperform rating to an in-line rating in a report on Friday, August 9th. Jefferies Financial Group boosted their target price on Hims & Hers Health from $14.00 to $23.00 and gave the stock a hold rating in a report on Thursday, June 27th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a hold rating in a report on Wednesday, August 7th. Finally, TD Cowen boosted their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a buy rating in a research note on Thursday, July 11th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $20.07.

Hims & Hers Health Trading Up 9.6 %

NYSE HIMS opened at $20.49 on Monday. The business’s 50-day moving average price is $16.46 and its 200 day moving average price is $17.42. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $25.74. The company has a market capitalization of $4.40 billion, a PE ratio of -2,049.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. During the same period last year, the company earned ($0.03) earnings per share. The company’s quarterly revenue was up 51.8% on a year-over-year basis. Equities analysts predict that Hims & Hers Health will post 0.22 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,335 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $20.29, for a total value of $47,377.15. Following the transaction, the insider now directly owns 166,809 shares of the company’s stock, valued at $3,384,554.61. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Soleil Boughton sold 2,335 shares of the business’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $20.29, for a total value of $47,377.15. Following the completion of the sale, the insider now owns 166,809 shares of the company’s stock, valued at approximately $3,384,554.61. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the transaction, the insider now directly owns 185,326 shares in the company, valued at $4,077,172. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 563,833 shares of company stock valued at $9,113,958. Insiders own 17.71% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its stake in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC raised its holdings in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares during the period. CWM LLC lifted its position in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the last quarter. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health in the 2nd quarter valued at about $111,000. Finally, Amalgamated Bank grew its position in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.